(NASDAQ: PRCT) Procept Biorobotics's forecast annual revenue growth rate of 23.07% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.44%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Procept Biorobotics's revenue in 2026 is $322,024,000.On average, 16 Wall Street analysts forecast PRCT's revenue for 2026 to be $23,159,139,247, with the lowest PRCT revenue forecast at $21,909,770,621, and the highest PRCT revenue forecast at $24,101,146,115. On average, 16 Wall Street analysts forecast PRCT's revenue for 2027 to be $28,551,061,339, with the lowest PRCT revenue forecast at $26,601,590,932, and the highest PRCT revenue forecast at $30,032,089,660.
In 2028, PRCT is forecast to generate $34,234,977,101 in revenue, with the lowest revenue forecast at $32,032,217,838 and the highest revenue forecast at $36,540,190,283.